Literature DB >> 9327033

Heparin therapy in the Chinese--lower doses are required.

C M Yu1, T Y Chan, W C Tsoi, J E Sanderson.   

Abstract

Warfarin requirements are lower in the Chinese, but it is not known if this applies to heparin. We investigated the optimal dose for heparin therapy in Chinese patients, and to assess relationship between i.v. heparin dosage and anticoagulation efficacy. One hundred Chinese patients requiring intravenous heparin therapy were given an initial bolus followed by continuous intravenous infusion. The main outcome measures were: (i) Efficacy of anticoagulation assessed by blood coagulation studies (APTT) compared to heparin dosage, (ii) Determinants of dosage variation-age, gender, body weight, height, indication for heparin therapy and number of medications, other disease, and serum albumin level. It was found that the mean therapeutic infusion dose requirement of heparin was 848.7 +/- 274.7 units/h, 79% required a dose of 1000 units/h or less. Heparin dose correlated negatively with age (r = -0.40; p < 0.001) and positively with weight (r = 0.44 p < 0.001) and height (r = 0.49; p < 0.001). Chinese subjects require lower heparin doses (about 800 units/h) than usually recommended for Caucasians (usual dose 1000-1500 units/h). This can be partly explained by the lower body weight in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9327033     DOI: 10.1093/qjmed/90.8.535

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  3 in total

1.  Pharmacogenetics and ethnically targeted therapies.

Authors:  Taslin Rahemtulla; Raj Bhopal
Journal:  BMJ       Date:  2005-05-07

Review 2.  The need for multicentre cardiovascular clinical trials in Asia.

Authors:  Joey S W Kwong; Cheuk-Man Yu
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

3.  Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study.

Authors:  So Yeon Lim; Kyeongman Jeon; Hee-Jin Kim; Seon Mi Kim; Junwhi Song; Jung Min Ha; Sang-Won Um; Won-Jung Koh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Gee Young Suh
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.